 

Active ingredient: Acetazolamide 

 

Form/Route: Tablets/Oral 

 

Recommended studies: 1 study 

 

Type of study: Fasting 
Design: Single-dose, two-way, crossover in-vivo 

Strength: 250 mg 

Subjects: Normal healthy males and females, general population 

Additional Comments: Females should not be pregnant or lactating, and if applicable, 
should practice abstention or contraception during the study. 

______________________________________________________________________________ 

 

Analytes to measure: Acetazolamide in plasma 

 

Bioequivalence based on (90% CI): Acetazolamide 

 

Waiver request of in-vivo testing: 125 mg based on (i) acceptable bioequivalence studies on 
the 250 mg strength, (ii) acceptable dissolution testing across all strengths, and (iii) proportional 
similarity in the formulations across all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each 
of all strengths of the test and reference products. Specifications will be determined upon review 
of the application. 

 


